Superworth

Madrigal Pharmaceuticals price to sales ratio MDGL

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
7.8×
Peer median
5.8×

Madrigal Pharmaceuticals' price to sales ratio is 7.8× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far7.8×7.8×18.2×
202518.4×14.9×96.2×
202488.9×81.9×99.6×
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
2020n/m a value too high to mean anything
2019n/m a value too high to mean anything
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
2016n/m a value too high to mean anything
2015n/m a value too high to mean anything
2014n/m a value too high to mean anything
2013170×150×199×
2012154×32.5×157×

Against its peers

Companies in Drug Manufacturers - General nearest Madrigal Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
MDGLMadrigal Pharmaceuticals7.8×
BMRNBiomarin Pharmaceutical3.2×
CORTCorcept Therapeutics11.2×
PTGXProtagonist Therapeutics31.8×
TGTXTG Therapeutics10.4×
ALKSAlkermes plc.4.4×
JAZZJazz Pharmaceuticals3.0×
AMRXAmneal Pharmaceuticals2.1×
LGNDLigand Pharmaceuticals20.8×
KNSAKiniksa Pharmaceuticals International7.1×
INDVIndivior Pharmaceuticals3.1×
Peer median5.8×

Where Madrigal Pharmaceuticals ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Madrigal Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.